Latest Tax Incentives News

Papyrus Australia has taken a significant step towards commercialisation with a $4.2 million supply contract and the near completion of its Adelaide Rapid Prototyping and R&D Facility.

CONNEQT Health Limited reported a strong quarter with over 200% sales growth for its CONNEQT Pulse product and completed a $3.1 million institutional placement, while operational cost reductions support a leaner business model.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Green360 Technologies has made significant strides in commercialising its low-carbon cement product Eco-Clay, delivering successful large-scale trials and securing a robust financial footing heading into 2026.

FortifAI Limited has acquired FastAI and its cutting-edge Nol8 Technology, driving a 14.7% revenue increase and delivering positive net operating cash flow for the first time in Q2 FY26.

Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.

Livium Ltd has solidified its position in the clean energy recycling sector with new contracts, a key patent, and a $4.5 million capital raise, setting the stage for accelerated growth in lithium-ion battery and rare earth element recycling.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Pilot Energy has made significant strides in Q4 2025 with the launch of a modular data centre joint venture, progress on a hybrid solar and battery project, and advancement of offshore gas exploration partnerships, supported by substantial new financing.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Entropy Neurodynamics has successfully enrolled and dosed the first patient in its pioneering clinical trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder, while securing $6.1 million in new funding to accelerate development.